|
|
|

|
Recommended
Immunization Schedule
Ages 0-6 Years
UNITED STATES 2008
|
|
|
This schedule indicates the recommended ages
for routine administration of currently licensed childhood
vaccines, as of December 1, 2007, for children aged 0
through 6 years. Additional information is available at
www.cdc.gov/vaccines/recs/schedules. Any dose not
administered at the recommended age should be administered
at any subsequent visit, when indicated and feasible.
Additional vaccines may be licensed and recommended during
the year. Licensed combination vaccines may be used whenever
any components of the combination are indicated and other
components of the vaccine are not contraindicated and if
approved by the Food and Drug Administration for that dose
of the series. Providers should consult the respective
Advisory Committee on Immunization Practices statement for
detailed recommendations, including for high risk
conditions:
www.cdc.gov/vaccines/pubs/ACIP-list.htm.
Clinically significant adverse events that follow
immunization should be reported to the Vaccine Adverse Event
Reporting System (VAERS). Guidance about how to obtain and
complete VAERS form is available at
www.vaers.hhs.gov or by telephone, 800-822-7967. |
|
|
|
|
|
|
|
|
1.
Hepatitis B vaccine (HepB).
(Minimum age: birth)
At birth:
- Administer monovalent HepB to all
newborns prior to hospital discharge.
- If mother is hepatitis B surface
antigen (HBsAg)-positive, administer HepB and 0.5 mL of
hepatitis B immune globulin (HBIG) within 12 hours of
birth.
- If mother’s HBsAg status is unknown,
administer HepB within 12 hours of birth. Determine the
HBsAg status as soon as possible and if HBsAg-positive,
administer HBIG (no later than age 1 week).
- If mother is HBsAg-negative, the
birth dose can be delayed, in rare cases, with a
provider’s order and a copy of the mother’s negative
HBsAg laboratory report in the infant’s medical record.
After the birth dose:
- The HepB series should be completed
with either monovalent HepB or a combination vaccine
containing HepB. The second dose should be administered
at age 1–2 months. The final dose should be administered
no earlier than age 24 weeks. Infants born to HBsAg-positive
mothers should be tested for HBsAg and antibody to HBsAg
after completion of at least 3 doses of a licensed HepB
series, at age 9–18 months (generally at the next
well-child visit).
4-month dose:
- It is permissible to administer 4
doses of HepB when combination vaccines are administered
after the birth dose. If monovalent HepB is used for
doses after the birth dose, a dose at age 4 months is
not needed.
2. Rotavirus vaccine
(Rota). (Minimum age: 6 weeks)
- Administer the first dose at age 612
weeks.
- Do not start the series later than age 12 weeks.
- Administer the final dose in the
series by age 32 weeks. Do not administer a dose later
than age 32 weeks.
- Data on safety and efficacy outside
of these age ranges are insufficient.
3. Diphtheria and tetanus toxoids and acellular pertussis
vaccine (DTaP). (Minimum age: 6 weeks)
4. Haemophilus influenzae type b conjugate vaccine (Hib).
(Minimum age: 6 weeks)
- If PRP-OMP (PedvaxHIB® or ComVax®
[Merck]) is administered at ages 2 and 4 months, a dose
at age 6 months is not required.
- TriHiBit® (DTaP/Hib) combination
products should not be used for primary immunization but
can be used as boosters following any Hib vaccine in
children aged ≥ 12 months.
5. Pneumococcal vaccine.
(Minimum age: 6 weeks
for pneumococcal conjugate vaccine [PCV]; 2 years for
pneumococcal polysaccharide vaccine [PPV])
6.
Influenza vaccine. (Minimum age: 6 months for
trivalent inactivated influenza vaccine [TIV]; 2 years for
live, attenuated influenza vaccine [LAIV])
- Administer annually to children
aged 6–59 months and to all close contacts of
children aged 0–59 months.
- Administer annually to children 5
years of age and older with certain risk factors, to
other persons (including household members) in close
contact with persons in groups at higher risk, and
to any child whose parents request vaccination.
- For healthy nonpregnant persons
(those who do not have underlying medical conditions
that predispose them to influenza complications)
ages 2–49 years, either LAIV or TIV may be used.
- Children receiving TIV should
receive 0.25 mL if age 6-35 mos or 0.5 mL if age 3
years or older.
- Administer 2 doses (separated by
4 weeks or longer) to children younger than 9 years
who are receiving influenza vaccine for the first
time or who were vaccinated for the first time last
season, but only received one dose.
7.
Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
- Administer the second dose of MMR at age 46 years. MMR
may be administered before age 46 years, provided
≥ 4 weeks
have elapsed since the first dose and both doses are
administered at age >12 months.
8.
Varicella vaccine. (Minimum age: 12 months)
- Administer second dose at age 46
years; may be administered ≥
3 months after first does.
- Don't repeat
second dose if administered ≥
28 days after first
dose.
9. Hepatitis A
vaccine (HepA). (Minimum age: 12 months)
- HepA is recommended for all children aged 1 year (i.e.,
aged 1223 months). The 2 doses in the series should be
administered at least 6 months apart.
- Children not fully vaccinated by age 2 years can be
vaccinated at subsequent visits.
- HepA is recommended for certain other groups of children,
including in areas where vaccination programs target older
children.
10. Meningococcal polysaccharide vaccine (MPSV4).
(Minimum age: 2 years for meningococcal conjugate vaccine
(MCV4) and for meningococcal polysaccharide
vaccine (MPSV4))
- MPSV4 is recommended
for children aged 210 years with terminal
complement deficiencies or anatomic or functional asplenia
and certain other high-risk groups. Use of MPSV4 is
also acceptable.
- Persons who received
MPSV4 ≥
3 years prior and remain at increased
risk for meningococcal disease should be
vaccinated with MSV4.
|
Changes from 2007 Schedule
- The pneumococcal
conjugate vaccine (PCV) footnote reflects
updated recommendations for incompletely
vaccinated children aged 24–59 months,
including those with underlying medical
conditions.
- Recommendations for use
of the live attenuated influenza vaccine (LAIV)
now include healthy children as young as 2
years. LAIV should not be administered to
children younger than 5 years with recurrent
wheezing. Children aged under 9 years who
are receiving influenza vaccine for the
first time or who were vaccinated for the
first time last season, but only received 1
dose, should have 2 doses of vaccine, at
least 4 weeks apart. Other updates are
included.
- For meningococcal
vaccines, changes affect certain children
aged 2–10 years. Vaccinating with
meningococcal conjugate vaccine (MCV4) is
preferred to meningococcal polysaccharide
vaccine (MPSV4) for children at increased
risk for meningococcal disease, including
children who are traveling to or residents
of countries in which the disease is
hyperendemic or epidemic, children who have
terminal complement component deficiencies,
and children who have anatomic or functional
asplenia.
|
|

This page
was last updated on
January 30, 2008 |
|